Nuclear Medicine/Radiopharmaceuticals Market Revenue and Share by Leading Players Cardinal Health, IBA Worldwide, Curium, Bayer AG

The nuclear imaging uses long lived gamma emitters, which allow blood clearance as the tumor increases its uptake of the conjugate over time, so improving contrast. The nuclear imaging agents allows dose to the tumor and organs to be determined. The high energy gamma rays are emitted from alpha emitters, which also allow dose estimates for organs and tumors. In addition, the rise in the awareness about the alpha radio immunotherapy and availability of the therapies for the cancer treatment procedures are likely to foster the demand for nuclear imaging. Thus, owing to these factors the market for the nuclear medicine/radiopharmaceuticals is likely to propel at a significant rate during the forecast period.

Download Sample PDF Copy @ https://bit.ly/3fjFhSW

NUCLEAR MEDICINE/RADIOPHARMACEUTICALS – MARKET SEGMENTATION

Global Nuclear Medicine/Radiopharmaceuticals Market – By Applications

Diagnostic Applications

SPECT (Single-Photon Emission Computed Tomography) Applications
PET (Positron Emission Tomography) Applications

Therapeutic Applications
Thyroid
Bone Metastasis
Lymphoma
Endocrine Tumors
Other Therapeutic Applications

Global Nuclear Medicine/Radiopharmaceuticals Market – By End User

Hospitals
Diagnostic Centers

The market for nuclear medicine/radiopharmaceuticals is expected to grow, owing to factors such as rising prevalence of chronic diseases, alpha radioimmunotherapy-based targeted oncology treatment and advancement in imaging technologies using radiopharmaceuticals play vital role in the growth of the radiopharmaceuticals market. However, the restraints such as short shelf-life of radiopharmaceuticals and availability of substitutes of radiopharmaceuticals are likely to impact the growth of the market in the forecast period.

The major players operating in the nuclear medicine/radiopharmaceuticals market include Cardinal Health, IBA Worldwide, Curium, GENERAL ELECTRIC, Bayer AG, Positron Corporation, NTP Radioisotopes SOC Ltd, Bracco, Lantheus Medical Imaging Inc., and Advanced Accelerator Applications. The market has witnessed various organic as well as inorganic developments during recent years in the nuclear medicine/radiopharmaceuticals market. During January 2019, Curium and Progenics entered into a collaboration to develop and commercialize PyL in Europe. This agreement has helped the companies to offer better products to its customers across the globe.

Purchase this Report @ https://bit.ly/3cZLbH7

Reason to Buy

- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Nuclear Medicine/Radiopharmaceuticals Market.

- Highlights key business priorities in order to guide the companies to reform their business strategies and establish themselves in the wide geography.

- The key findings and recommendations highlight crucial progressive industry trends in the Nuclear Medicine/Radiopharmaceuticals Market, thereby allowing players to develop effective long term strategies in order to garner their market revenue.

- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those restraining the growth at a certain extent.

- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to products, segmentation and industry verticals.

Contact Us:
The Insight partners,
Phone: +16464919876
Email: sales@theinsightpartners.com

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

This release was published on openPR.